Intrinsic value of MediWound - MDWD

Previous Close

$5.84

  Intrinsic Value

$0.08

stock screener

  Rating & Target

str. sell

-99%

Previous close

$5.84

 
Intrinsic value

$0.08

 
Up/down potential

-99%

 
Rating

str. sell

We calculate the intrinsic value of MDWD stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  4
  6
  9
  13
  19
  26
  35
  46
  59
  74
  92
  113
  136
  162
  190
  222
  255
  291
  330
  371
  414
  460
  508
  558
  610
  665
  722
  781
  843
  907
Variable operating expenses, $m
  56
  86
  129
  187
  264
  363
  487
  640
  823
  1,040
  1,291
  1,578
  1,902
  2,263
  2,661
  3,096
  3,566
  4,071
  4,611
  5,184
  5,790
  6,428
  7,098
  7,798
  8,531
  9,294
  10,089
  10,916
  11,776
  12,670
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  56
  86
  129
  187
  264
  363
  487
  640
  823
  1,040
  1,291
  1,578
  1,902
  2,263
  2,661
  3,096
  3,566
  4,071
  4,611
  5,184
  5,790
  6,428
  7,098
  7,798
  8,531
  9,294
  10,089
  10,916
  11,776
  12,670
Operating income, $m
  -52
  -80
  -120
  -174
  -245
  -337
  -452
  -594
  -764
  -965
  -1,199
  -1,465
  -1,766
  -2,101
  -2,471
  -2,874
  -3,311
  -3,780
  -4,281
  -4,813
  -5,376
  -5,968
  -6,590
  -7,240
  -7,920
  -8,629
  -9,367
  -10,135
  -10,933
  -11,763
EBITDA, $m
  -51
  -79
  -118
  -171
  -241
  -332
  -445
  -585
  -753
  -951
  -1,180
  -1,443
  -1,740
  -2,070
  -2,434
  -2,831
  -3,261
  -3,723
  -4,217
  -4,741
  -5,295
  -5,878
  -6,491
  -7,131
  -7,801
  -8,499
  -9,226
  -9,982
  -10,769
  -11,586
Interest expense (income), $m
  0
  0
  -1
  0
  1
  3
  4
  7
  10
  13
  17
  23
  28
  35
  43
  51
  61
  71
  82
  94
  106
  120
  134
  149
  165
  181
  199
  217
  235
  255
  275
Earnings before tax, $m
  -52
  -80
  -120
  -175
  -248
  -341
  -459
  -603
  -777
  -983
  -1,221
  -1,494
  -1,801
  -2,144
  -2,522
  -2,935
  -3,382
  -3,862
  -4,375
  -4,920
  -5,496
  -6,102
  -6,739
  -7,405
  -8,101
  -8,827
  -9,583
  -10,370
  -11,188
  -12,038
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -52
  -80
  -120
  -175
  -248
  -341
  -459
  -603
  -777
  -983
  -1,221
  -1,494
  -1,801
  -2,144
  -2,522
  -2,935
  -3,382
  -3,862
  -4,375
  -4,920
  -5,496
  -6,102
  -6,739
  -7,405
  -8,101
  -8,827
  -9,583
  -10,370
  -11,188
  -12,038

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  27
  42
  62
  90
  128
  175
  236
  309
  398
  503
  624
  763
  920
  1,094
  1,287
  1,497
  1,724
  1,969
  2,229
  2,507
  2,800
  3,108
  3,432
  3,771
  4,125
  4,494
  4,878
  5,278
  5,694
  6,126
Adjusted assets (=assets-cash), $m
  27
  42
  62
  90
  128
  175
  236
  309
  398
  503
  624
  763
  920
  1,094
  1,287
  1,497
  1,724
  1,969
  2,229
  2,507
  2,800
  3,108
  3,432
  3,771
  4,125
  4,494
  4,878
  5,278
  5,694
  6,126
Revenue / Adjusted assets
  0.148
  0.143
  0.145
  0.144
  0.148
  0.149
  0.148
  0.149
  0.148
  0.147
  0.147
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
  0.148
Average production assets, $m
  4
  6
  9
  13
  18
  25
  34
  45
  57
  73
  90
  110
  133
  158
  186
  216
  249
  284
  322
  362
  404
  449
  496
  545
  596
  649
  705
  762
  822
  885
Working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  2
  2
  2
  3
  3
  3
  4
  4
  5
  5
  5
  6
  6
  7
  8
  8
Total debt, $m
  -10
  3
  22
  47
  80
  123
  177
  244
  324
  418
  527
  652
  793
  950
  1,124
  1,313
  1,517
  1,737
  1,972
  2,221
  2,485
  2,763
  3,054
  3,359
  3,678
  4,010
  4,356
  4,716
  5,090
  5,479
Total liabilities, $m
  24
  38
  56
  81
  115
  158
  212
  278
  358
  452
  562
  687
  828
  985
  1,158
  1,347
  1,552
  1,772
  2,007
  2,256
  2,520
  2,797
  3,089
  3,394
  3,712
  4,044
  4,390
  4,750
  5,124
  5,513
Total equity, $m
  3
  4
  6
  9
  13
  18
  24
  31
  40
  50
  62
  76
  92
  109
  129
  150
  172
  197
  223
  251
  280
  311
  343
  377
  412
  449
  488
  528
  569
  613
Total liabilities and equity, $m
  27
  42
  62
  90
  128
  176
  236
  309
  398
  502
  624
  763
  920
  1,094
  1,287
  1,497
  1,724
  1,969
  2,230
  2,507
  2,800
  3,108
  3,432
  3,771
  4,124
  4,493
  4,878
  5,278
  5,693
  6,126
Debt-to-equity ratio
  -3.790
  0.720
  3.460
  5.180
  6.300
  7.030
  7.530
  7.880
  8.130
  8.310
  8.450
  8.550
  8.620
  8.680
  8.730
  8.770
  8.800
  8.820
  8.850
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.920
  8.930
  8.930
  8.940
  8.940
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -52
  -80
  -120
  -175
  -248
  -341
  -459
  -603
  -777
  -983
  -1,221
  -1,494
  -1,801
  -2,144
  -2,522
  -2,935
  -3,382
  -3,862
  -4,375
  -4,920
  -5,496
  -6,102
  -6,739
  -7,405
  -8,101
  -8,827
  -9,583
  -10,370
  -11,188
  -12,038
Depreciation, amort., depletion, $m
  1
  1
  2
  3
  4
  5
  7
  9
  12
  15
  18
  22
  27
  32
  37
  43
  50
  57
  64
  72
  81
  90
  99
  109
  119
  130
  141
  152
  164
  177
Funds from operations, $m
  -51
  -78
  -118
  -172
  -244
  -336
  -452
  -594
  -766
  -968
  -1,203
  -1,472
  -1,775
  -2,113
  -2,485
  -2,892
  -3,332
  -3,805
  -4,311
  -4,847
  -5,415
  -6,012
  -6,640
  -7,296
  -7,982
  -8,698
  -9,442
  -10,218
  -11,023
  -11,861
Change in working capital, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
Cash from operations, $m
  -51
  -78
  -118
  -172
  -244
  -336
  -452
  -595
  -766
  -968
  -1,203
  -1,472
  -1,775
  -2,113
  -2,485
  -2,892
  -3,332
  -3,805
  -4,311
  -4,848
  -5,415
  -6,013
  -6,640
  -7,297
  -7,983
  -8,698
  -9,443
  -10,218
  -11,024
  -11,862
Maintenance CAPEX, $m
  0
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -15
  -18
  -22
  -27
  -32
  -37
  -43
  -50
  -57
  -64
  -72
  -81
  -90
  -99
  -109
  -119
  -130
  -141
  -152
  -164
New CAPEX, $m
  -2
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -13
  -15
  -18
  -20
  -23
  -25
  -28
  -30
  -33
  -35
  -38
  -40
  -42
  -45
  -47
  -49
  -51
  -53
  -56
  -58
  -60
  -62
Cash from investing activities, $m
  -2
  -3
  -4
  -6
  -8
  -11
  -14
  -18
  -22
  -26
  -33
  -38
  -45
  -52
  -60
  -67
  -76
  -85
  -95
  -104
  -114
  -126
  -137
  -148
  -160
  -172
  -186
  -199
  -212
  -226
Free cash flow, $m
  -53
  -81
  -122
  -178
  -252
  -347
  -466
  -612
  -788
  -995
  -1,235
  -1,510
  -1,820
  -2,165
  -2,545
  -2,959
  -3,408
  -3,891
  -4,405
  -4,952
  -5,530
  -6,138
  -6,777
  -7,445
  -8,143
  -8,871
  -9,628
  -10,417
  -11,237
  -12,089
Issuance/(repayment) of debt, $m
  -10
  13
  19
  25
  33
  43
  54
  66
  80
  94
  109
  125
  141
  157
  173
  189
  205
  220
  235
  249
  264
  278
  291
  305
  319
  332
  346
  360
  374
  389
Issuance/(repurchase) of shares, $m
  76
  81
  122
  178
  251
  346
  465
  611
  786
  993
  1,233
  1,508
  1,817
  2,162
  2,541
  2,956
  3,404
  3,886
  4,401
  4,947
  5,525
  6,133
  6,771
  7,439
  8,137
  8,864
  9,622
  10,410
  11,229
  12,081
Cash from financing (excl. dividends), $m  
  66
  94
  141
  203
  284
  389
  519
  677
  866
  1,087
  1,342
  1,633
  1,958
  2,319
  2,714
  3,145
  3,609
  4,106
  4,636
  5,196
  5,789
  6,411
  7,062
  7,744
  8,456
  9,196
  9,968
  10,770
  11,603
  12,470
Total cash flow (excl. dividends), $m
  12
  13
  18
  25
  33
  42
  53
  65
  78
  93
  107
  123
  138
  154
  170
  185
  201
  216
  230
  245
  259
  272
  286
  299
  313
  326
  339
  353
  367
  382
Retained Cash Flow (-), $m
  -76
  -81
  -122
  -178
  -251
  -346
  -465
  -611
  -786
  -993
  -1,233
  -1,508
  -1,817
  -2,162
  -2,541
  -2,956
  -3,404
  -3,886
  -4,401
  -4,947
  -5,525
  -6,133
  -6,771
  -7,439
  -8,137
  -8,864
  -9,622
  -10,410
  -11,229
  -12,081
Prev. year cash balance distribution, $m
  31
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -33
  -68
  -104
  -153
  -219
  -304
  -412
  -546
  -708
  -901
  -1,126
  -1,385
  -1,679
  -2,008
  -2,371
  -2,770
  -3,204
  -3,671
  -4,171
  -4,703
  -5,266
  -5,861
  -6,485
  -7,140
  -7,824
  -8,538
  -9,282
  -10,057
  -10,862
  -11,700
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -32
  -62
  -90
  -126
  -169
  -220
  -278
  -341
  -407
  -472
  -535
  -591
  -638
  -674
  -696
  -704
  -697
  -676
  -642
  -598
  -545
  -486
  -425
  -364
  -304
  -249
  -199
  -156
  -119
  -88
Current shareholders' claim on cash, %
  50.0
  12.5
  3.2
  0.8
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

FINANCIAL RATIOS  of  MediWound (MDWD)

Valuation Ratios
P/E Ratio -6.7
Price to Sales 64
Price to Book 16
Price to Tangible Book
Price to Cash Flow -8
Price to Free Cash Flow -7.5
Growth Rates
Sales Growth Rate 100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -42.7%
Ret/ On Assets - 3 Yr. Avg. -40.8%
Return On Total Capital -122.6%
Ret/ On T. Cap. - 3 Yr. Avg. -118.2%
Return On Equity -122.6%
Return On Equity - 3 Yr. Avg. -118.2%
Asset Turnover 0
Profitability Ratios
Gross Margin -50%
Gross Margin - 3 Yr. Avg. -83.3%
EBITDA Margin -900%
EBITDA Margin - 3 Yr. Avg. -1000%
Operating Margin -1000%
Oper. Margin - 3 Yr. Avg. -1033.3%
Pre-Tax Margin -950%
Pre-Tax Margin - 3 Yr. Avg. -1050%
Net Profit Margin -950%
Net Profit Margin - 3 Yr. Avg. -1050%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

MDWD stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDWD stock intrinsic value calculation we used $2.496 million for the last fiscal year's total revenue generated by MediWound. The default revenue input number comes from 0001 income statement of MediWound. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDWD stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MDWD is calculated based on our internal credit rating of MediWound, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of MediWound.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDWD stock the variable cost ratio is equal to 1400%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MDWD stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for MediWound.

Corporate tax rate of 27% is the nominal tax rate for MediWound. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDWD stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDWD are equal to 97.6%.

Life of production assets of 4.1 years is the average useful life of capital assets used in MediWound operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDWD is equal to 0.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $9.62 million for MediWound - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 27.048 million for MediWound is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of MediWound at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
SNN Smith&Nephew A 36.55 255.74  str.buy

COMPANY NEWS

▶ MediWound: 3Q Earnings Snapshot   [07:14AM  Associated Press]
▶ MediWound: 2Q Earnings Snapshot   [09:02AM  Associated Press]
▶ MediWound Ltd. to Host Earnings Call   [06:30AM  ACCESSWIRE]
▶ MediWound: 1Q Earnings Snapshot   [May-10-18 07:48AM  Associated Press]
▶ MediWound reports 4Q loss   [07:19AM  Associated Press]
▶ MediWound Ltd. to Host Earnings Call   [06:45AM  ACCESSWIRE]
▶ MediWound to Present at Two Investor Conferences   [Mar-08-18 04:05PM  GlobeNewswire]
▶ MediWound reports 3Q loss   [Nov-16-17 07:17AM  Associated Press]
▶ All You Need To Know About MediWound Ltds (MDWD) Risks   [Sep-19-17 10:09AM  Simply Wall St.]
▶ MediWound Ltd. Announces Public Offering of Ordinary Shares   [Sep-18-17 04:07PM  GlobeNewswire]
▶ MediWound reports 2Q loss   [Aug-04-17 02:32AM  Associated Press]
▶ MediWound Reports Second Quarter 2017 Financial Results   [Aug-03-17 07:00AM  GlobeNewswire]
▶ MediWound Announces Changes to its Board of Directors   [May-18-17 08:01AM  GlobeNewswire]
▶ MediWound reports 1Q loss   [07:08AM  Associated Press]
▶ MediWound reports 4Q loss   [09:33AM  Associated Press]
▶ Here is What Hedge Funds Think About Era Group Inc (ERA)   [Dec-14-16 06:21AM  at Insider Monkey]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.